In a public statement published on its website and online wire services, Kurin, Inc. CEO Bob Rogers addressed the patent infringement case that sepsis test products competitor Magnolia Medical (maker of Steripath) has filed against Kurin. What follows are excerpts from his pubic address.
“First, the timing of the suit is not a coincidence. For the first year, Magnolia harshly attacked the Kurin Lock design, claiming that the diversion volume was too low to reduce contaminations and that because the Kurin Lock does not completely isolate blood it cannot work. With our continued clinical success these arguments have been proven false, and now they are undermining Magnolia’s reputation.
Several Steripath hospitals, across the country, have recently switched to Kurin because they are getting the same or better clinical results and clinicians are much happier with the simplicity of Kurin.
At Kurin, we respect the intellectual property rights of others. This is apparent in the design of the Kurin Lock, which is fundamentally different from Steripath in concept and operation, and which Magnolia previously claimed would not work.
We firmly believe that the Kurin Lock does not infringe any Magnolia patent, and we remain confident that this position will be proven out in the courts.
Our team at Kurin has a great deal of patent litigation experience. At our last company, Ivera Medical (the Curos green cap designed to decrease bloodstream infections), we created a whole new class of medical devices and with our success many tried to copy us. We were involved in multiple infringement cases (both on offense and defense) and when the dust settled, we prevailed.”
